MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Alkermes PLC

Aperta

SettoreSettore sanitario

30.09 -4.69

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.66

Massimo

31.79

Metriche Chiave

By Trading Economics

Entrata

54M

147M

Vendite

52M

430M

P/E

Media del settore

15.078

63.778

EPS

1.05

Margine di Profitto

34.072

Dipendenti

1,800

EBITDA

58M

181M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+19.88% upside

Dividendi

By Dow Jones

Utili prossimi

30 apr 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

298M

5.4B

Apertura precedente

34.78

Chiusura precedente

30.09

Notizie sul Sentiment di mercato

By Acuity

36%

64%

118 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Alkermes PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 apr 2025, 23:04 UTC

Notizie principali

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 apr 2025, 22:40 UTC

I principali Market Mover

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 apr 2025, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 apr 2025, 18:51 UTC

Acquisizioni, Fusioni, Takeovers

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

4 apr 2025, 00:00 UTC

Notizie principali

Resistance Is Futile, Make a Deal: Trump's Tariff Message to the World -- WSJ

3 apr 2025, 23:43 UTC

Discorsi di Mercato

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 apr 2025, 23:41 UTC

Discorsi di Mercato

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 apr 2025, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 21:43 UTC

Notizie principali
Utili

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

3 apr 2025, 20:43 UTC

Discorsi di Mercato

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 apr 2025, 20:34 UTC

Notizie principali

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 apr 2025, 20:23 UTC

Notizie principali

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 apr 2025, 19:55 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2025, 19:55 UTC

Discorsi di Mercato

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 apr 2025, 19:21 UTC

Discorsi di Mercato

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 apr 2025, 19:15 UTC

Discorsi di Mercato

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 apr 2025, 18:45 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:45 UTC

Discorsi di Mercato

Gold Drops In Tariff Fallout -- Market Talk

3 apr 2025, 18:39 UTC

Discorsi di Mercato

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 apr 2025, 18:38 UTC

Notizie principali

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 18:30 UTC

Notizie principali

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 apr 2025, 18:20 UTC

Discorsi di Mercato

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 apr 2025, 18:18 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:17 UTC

Discorsi di Mercato

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 apr 2025, 18:04 UTC

Discorsi di Mercato

US Sees More Job Openings in Construction, Transportation -- Market Talk

Confronto tra pari

Modifica del prezzo

Alkermes PLC Previsione

Obiettivo di Prezzo

By TipRanks

19.88% in crescita

Previsioni per 12 mesi

Media 39.14 USD  19.88%

Alto 52 USD

Basso 30 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Alkermes PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

14 ratings

8

Acquista

6

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

32.24 / 33.7Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

118 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.